<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04028024</url>
  </required_header>
  <id_info>
    <org_study_id>B2019-156</org_study_id>
    <nct_id>NCT04028024</nct_id>
  </id_info>
  <brief_title>Protective Effect in Cardiac Surgery Patients</brief_title>
  <official_title>Study on the Protective Effect of Inhibiting Systemic Inflammatory Response in Patients Undergoing Cardiac Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to verify the protective effect of inhibiting systemic
      inflammatory response in patients undergoing cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative delirium</measure>
    <time_frame>7 days postoperatively or discharge, whichever came first</time_frame>
    <description>the incidence of postoperative delirium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative renal insufficiency</measure>
    <time_frame>7 days postoperatively or discharge, whichever came first</time_frame>
    <description>the incidence of renal insufficiency</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>inhibiting systemic inflammatory response</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ulinastatin 5000U/kg in 20ml NS i.v. before occlusion of aorta</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulinastatin</intervention_name>
    <description>Ulinastatin 5000U/Kg in 20 ml NS i.v. before occlusion of aorta</description>
    <arm_group_label>inhibiting systemic inflammatory response</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject needs to have valve surgery

          -  subject needs to have coronary artery bypass grafting surgery

          -  subject needs to have artificial blood vessel replacement surgery

          -  ASA(American Society of Anesthesiologists) score II~III

          -  NYHA(New York Heart Association) II~III

        Exclusion Criteria:

          -  LVEF(left ventricular ejection fraction) &lt;40% measured by echocardiogram

          -  history of myocardial infarction within 1 month

          -  history of serious pulmonary infection or endocarditis within 3 months

          -  history of important surgery within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui-lin Wang, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ke-fang Guo, PhD</last_name>
    <phone>64041990</phone>
    <email>Guo.kefang@zs-hospital.sh.cn</email>
  </overall_contact>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 14, 2019</study_first_submitted>
  <study_first_submitted_qc>July 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

